TREGeneration Goals and Objectives

Our project aims to treat tissue and organ damage associated with acute (aGVHD) and, mostly, chronic graft versus host disease (cGVHD) after hematopoietic stem cell transplantation (HSCT) by the infusion of regulatory T lymphocytes (Treg) purified from the peripheral blood of the original hematopoietic stem cell donor.

 

The TREGeneration study proposes the following objectives and goals:

 

  • Development  according  to  GMP  standards  of  different  Treg  cell  products  from  HSCT  donors  for  infusion  into patients with steroid-refractory aGVHD and cGVHD (undefinedWork Package 1)
  • Evaluate  the  safety,  toxicity  and  efficacy  of  infusing  different  populations  of  donor  Treg  into  patients  with  steroid-refractory aGVHD and cGVHD (undefinedWork Package 2)
  • Evaluate the effect of donor Treg infusion in reversal of tissue damage due to aGVHD and cGVHD (undefinedWork Package 3)
  • Evaluate the effect of donor Treg infusion in the immune function of patients with aGVHD and cGVHD (undefinedWork Package 3)
  • In vivo tracking  of  specific  TCR  clonotypes  of  naive  and  memory  Treg,  CD4+  non-Treg  (Tcon)  and  CD8+  T  cells  by Next Generation Sequencing in patients with aGVHD and cGVHD (undefinedWork Package 4)

 

The TREGeneration partners

Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

Paul Ehrlich Institute approves cGVHD Trial Read more

Social Media

LinkedIn TREGeneration